Medicinal Product For Autologous Cell Therapy - Brexukabtagen Autoleucel - 2025. The Subject Of The Public Contract Is The Supply Of A Medicinal Product Intended For The Therapy Of Malignant Blood Diseases In The Total Expected Volume Of 16 Individual Doses Of The Medicinal Product. The Preparation Is Intended For The Provision Of Health Care At The Medical Workplace Of The Fn Plzeň. Cytostatic Agent For Car-T Therapy (Brexukabtagen Autoleucel) - Infusion Bag Containing A Cell Dispersion Of 0.4 - 2X10^8 Viable Anti-Cd19 Car-Positive T-Lymphocytes. The Expected Annual Volume Is 4 Infusion Bags Containing An Individually Determined Amount Of The Active Ingredient, Atc L01xl06. Deliveries Of The Subject Of Performance Will Be Carried Out On The Basis Of The Results Of The Completed Procurement Procedure For A Period Of Four Years From The Signing Of The Purchase Contract.
Contact Information
Contact Person
Mgr. Matěj Novák
Email
novakma@fnplzen.cz
View Notice Now...
Fill Detail for Getting Instant Access
Download Tender Document / Tender Notice
Dear Sir,
Warm Greetings from TenderDetail.com !!
We have received Tender Document request for the TDR No : 106567059
Tender Notice along with it's Attachments ( Tender Document / Scan Image of News Paper)
sent to your Email Address :.
Please check your email for Tender Document.
